

# STUDY REFERENCE: VV\_CC-HRIPT/50D1\_699\_21\_001

Study Report - Version nº 2

# ASSESSMENT IN HUMANS OF THE CUTANEOUS COMPATIBILITY AND THE ABSENCE OF ALLERGENIC POTENTIAL OF A COSMETIC PRODUCT AFTER REPEATED UNDER PATCH APPLICATIONS WITH DERMATOLOGICAL CONTROL

HUMAN REPEATED INSULT PATCH TEST (HRIPT)



# SPONSOR: NANO Z COATINGS LTD TESTED ELEMENT: HWC - DRY CLOTH SOAKED IN SOAP REFERENCE: -

Madrid, October 15<sup>th</sup>, 2021

All the changes on the present report respect to the previous version are indicated in italics

The present report is protected under Intellectual Property rights in favor of Zurko Research SL, reason why it is not authorized the total or partial reproduction of the same by unauthorized third parties, except for the client and exclusively for the execution of the project for which he was hired



# **REPORT INDEX**

1.	SYNOPSYS	3
2.	OBJECTIVE AND PRINCIPLE OF THE STUDY	4
3.	PANELISTS	4
4.	METHODOLOGY	6
5.	RESULTS	10
6.	SAMPLES AND DOCUMENTS TO BE STORED	11
7.	BIBLIOGRAPHICAL REFERENCES	11
SIGN	NATURES	12
Ann	nex I: Information relating to panelists	13
Ann	nex II: Individual results from Induction phase	15
Ann	nex III: Individual Results from Challenge phase	19



## 1. SYNOPSYS

SPONSOR	NANO Z COATINGS LTD
	Product name: HWC - DRY CLOTH SOAKED IN SOAP
Tested product	Product reference: -
	Batch: 2923
	ZURKO RESEARCH S.L
Testing Facility	Avenida de la Osa Mayor, 4. 28023, Madrid (España)
	Tel: (+34) 91.521.15.88
	Laboratory director: María Barbero Calderón, pharmacist
	Tolerance Department manager: Jesús González Cuartero, pharmacist
Technical team	Researcher: Jesús González Cuartero, pharmacist
	Technician: Ainhoa Yepes Agudo, Inés Rodríguez de Roa Peñarando
	Dermatologist: Javier Pedraz Muñoz. Medical license number: 283706434
Study code	VV_CC-HRIPT/50D1_699_21_001
	Number of panelists enrolled: 61
	Gender: both
Panelists	Age range: 18-70 years
	Skin type: sensitive skin according to center criteria
	Number of panelists completed: 52
Test area	Upper back
	Duration: 40 days
Application	Frequency: repeated applications under patch
Test period	August 30 <sup>th</sup> , 2021 –October 7 <sup>th</sup> , 2021
Test period	Final report version no. 1: October 14 <sup>th</sup> , 2021
Test parameters	Cutaneous evaluation of erythema and oedema
	Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 36 – Sample preparation and application
Design of study	Day 3, 5, 8, 10, 12, 15, 17, 19, 22, 36, 38, 39, 40 – Clinical and
	dermatological evaluation
Evaluation	Cutaneous Mean Irritation Index (M.I.I.) and allergenicity
Decultor	

# **Results:**

Under adopted experimental conditions, the product, *HWC - DRY CLOTH SOAKED IN SOAP*, reference: - has **Intermediate Cutaneous Compatibility**, **31%** of the panelists showed some kind of erythema or oedema reaction to the product during the induction phase.

Under the experimental conditions adopted, **No allergenicity** has been observed in any of the tested panelists.



## 2. OBJECTIVE AND PRINCIPLE OF THE STUDY

This study had as an objective verifying the cutaneous compatibility and the absence of allergenic potential of a cosmetic product after repeated skin applications, under exaggerated experimental conditions.

The product was applied to the skin under patch 9 times during 3 consecutive weeks. After a minimum of two weeks of rest with the patch application, the product was reapplied under patch in duplicate sites.

The compatibility of the product with the skin was verified, after removing the patch, and through visual examination of the experimental area, by the responsible technical expert and the dermatologist in charge of the study.

The method used is an adaptation of the one described by Marzulli and Maibach (Marzulli F.N., Maibach H.I., Contact allergy: predictive testing in man, Contact dermatitis, 1976, 2, pp.1-17).

The study was carried out following general conditions in Zurko Research, established for the execution of study project on humans (Structure and Content of Clinical Study Reports from ICH Harmonised Tripartite Guideline; Guideline for good clinical practice E6 (R2) of June 14th 2017, EMA/CHMP/ICH/135/1995 of May 1st 1996, European Parliament and Council Guideline 2001/20/CE – May 1st 2001).

The negative control excluded false positives.

## **3.** PANELISTS

## 3.1. Ethical aspects

Each participating panelist in the study was previously informed about the type and the procedures of the study and signed an Informed Consent Form before the beginning of the study.

## 3.2. Specific inclusion and exclusion criteria

The <u>specific inclusion criteria</u>, defined in the protocol, were as follow:

- Age: 18-70 years old
- Photo-type (Fitzpatrick): I to IV
- Skin type: sensitive skin according to center criteria

The <u>specific exclusion criteria</u>, defined in the protocol, were as follow:

- Cutaneous marks on the experimental area that could interfere with the evaluation of the skin reactions (pigmentation disruptions, scars, excessive hair areas, excessive freckles and moles, solar skin burns, tattoos...)
- Injuries, pathologies or infection in the experimental area
- Eczematous reaction which has not fully disappeared, scar or pigmentation complications from previous studies in the experimental area

Page 4 of 20



- Have the intention of bathing in bathtub, sea or pool or going to sauna or Turkish bath during the study
- Intense sun exposure or UV rays during the study, or having sunbathed or UV rays during the month prior to the study on the test area
- Carrying out a treatment containing acid vitamin A or its by-products, during the 3 months previous to the study
- Carrying out a treatment containing topical corticoids, on the experimental area during the 8 days previous to the beginning of the study
- Carrying out a treatment with any medicine for psoriasis or vitiligo, during the month previous to the study
- Having the intention to be vaccinated during the study or have been vaccinated during the 3 weeks previous to the study
- Being pregnant or breastfeeding period
- Allergies to metals
- Reactivity to medical tape
- Participation during the previous 30 days in any study under exaggerated conditions (under a patch).

Information about the participating panelist is included in Annex I.

Page 5 of 20



#### 4. METHODOLOGY

# **4.1.** Criteria for application the product

Type of product: textile fabric.

Product preparation: the sample is cut in pieces of 0,25 cm<sup>2</sup>.

<u>Applied quantity</u>: a piece of 0,25 cm<sup>2</sup> prepared over occlusive patch (Finn Chamber Aqua<sup>®</sup> occlusive patch).

## 4.2. Chronology of the study

Test duration: 6-8 consecutive weeks (40 days) without considering the re-challenge phase.

First phase: Induction Phase lasts three weeks:

- Application of the product under patch on days 1, 3, 5, 8, 10, 12, 15, 17, 19.
- Patch removal by the panelist at home on days 2, 4, 6, 9, 11, 13, 16, 18, 20 (after 24 hours of the application of the patch).
- Skin examination at 24 hours after patch removal on days 3, 5, 10, 12, 17, 19.
- Skin examination at 48 hours after patch removal on days 8, 15, 22.
- If excessive irritation develops anywhere, the product that cause the irritation is not reapplied and the panelist is excluded from the study.

**Second phase: Rest phase**. The duration was minimum 2 consecutive weeks and maximum 4. In this phase the product under study was not applied.

#### Third phase: Challenge or Memory phase: 1 week.

- Skin examination and application of the product under patch on Monday. The patch is applied in two areas, the induction area and the virgin area
- Patch removal by the panelist him/herself at home after 24 hours of the application.
- Skin examination 24 and 48 hours after the patch removal. 72 hours after the patch removal the skin is examined in those panelists who were reactive during the memory phase. For those panelists in which no reaction was observed, a negative result is assumed also on 72 hours.

Alternatively, the fourth phase: **Re-challenge phase.** It can be performed between 4 and 12 weeks after the initial challenge phase. Panelists who exhibit in challenge phase an inconclusive response and/or more information about challenge response is needed, a re-challenge can be performed between 4 and 12 weeks after the initial challenge phase. The experimental procedure is the same that challenge phase.

Page 6 of 20



# 4.3. Experimental procedure

		Day
	Informed Consent Form signature	1
Induction	Specific inclusion and exclusion criteria	1
	Patch application	1, 3, 5, 8, 10, 12, 15, 17, 19
	Evaluation after 24 hours of the patch removal by the panelists their selves and before reapply the patch	3, 5, 8, 10, 12, 15, 17, 19, 22
	Two weeks rest	
Challenge	Duplicate patch application	36
	Evaluation after 24 hours of the patch removal	38, 39, 40

Each day of evaluation the product is assigned an erythema score according the following scale:

Score	Assessment	PARAMETERS E	VALUATED
Score	of reaction	Erythema (E)	Oedema (OE)
0	Absence	No visible erythema	No visible oedema
1	Slight	Slight erythema (quiet pinked coloration of the complete tested area or rather visible on one part of the tested area)	Slight oedema (palpable and visible)
2	Moderate	Obvious erythema (clear erythema covering all of the tested area)	Obvious oedema with or without vesicle/s
3	Severe	Intense erythema (severe erythema covering all the tested area or erythema diffusing outside the tested area)	Intense oedema (extended area outside the tested area) with or without vesicle/s or blister/s

Table 1. Clinical Examination of Erythema and Oedema Scoring

Page 7 of 20



Other elevated responses could be observed, if present, are graded as independent responses:

- o P Papules many small, red, solid elevations; surface of reaction has granular feeling
- PU Pustules small, circumscribed, elevated and inflamed skin lesions, with pus at its centre.
- V Vesicles small, circumscribed elevations having translucent surfaces so that fluid is visible (blister like). Vesicles are no larger than 0.5 cm in diameter.
- B Bullae vesicles with a diameter> 0.5 cm; vesicles may coalesce to form one or a few large blisters that fill the patch site.

Other responses could be observed:

- S Spreading evidence of the reaction beyond the patch area
- W Weeping evidence of release of fluid from a vesicular or bullous reaction
- A Marked reaction to adhesive (patch relocated).
- X Succeeding patch not applied and succeeding grade is for residual reaction

#### 4.4. Interpretation of Results

The interpretation of the results of an HRIPT was carried out on a case-by-case basis using immunological principles, general interpretation guidelines and experience. The standard scoring scale used to interpret skin responses was provided in Table 1 and Table 2.

The following guidelines have been developed for the interpretation of reactions that may occur during an HRIPT.

- Skin sensitization reactions are most frequently erythematous, papular and edematous. Conversely, primary irritation reactions (unless severe), are generally erythematous only. An irritation reaction is usually uniform with a well-defined border, whereas an allergic response (especially if weak) is typically non-uniform and has an irregular border, and a strong response may spread beyond the patch site.
- Responses which are more severe at challenge than in early induction are suggestive of induction of skin sensitization.
- Responses confined to induction site during challenge phase are suggestive of irritation. True allergic reactions in challenge phase will occur at both site (induction site and virgin site) and persist through 2 delayed scorings at least 24 hours apart. However, unilateral allergic reactions can sometimes be observed. For this reason, all reactions considered suggestive of induction of skin sensitization should be followed up, for example, by rechallenge.
- Responses that increase or maintain severity with time from the 48 to 96 hours challenge gradings are presumptive of skin sensitization. Those that subside from the 48 to 96 hours grading period are generally considered to be irritant in nature.
- Edematous reactions that occur and persist during the latter part of the induction phase and the challenge phase are indicative of induced skin sensitization and should be confirmed by re-challenge.

Page 8 of 20



- Persistent skin responses with papules and/or edema occurring in week 1 of induction suggest pre-existing skin sensitization. Similar reactions that occur later in induction suggest induction of skin sensitization by the test material.
- Reactions and reaction patterns that are suggestive of allergic reactions or questionable/equivocal reactions should be verified through appropriate re-challenge procedures.
- The reactions of any panelist(s) in question should always be compared with those of all other exposed panelists. Except in rare instances, allergic reactivity occurs in only a very small number of subjects, while irritation occurs more widely throughout the exposed population.

The HRIPT objective was to verify the absence of allergenic potential and the skin sensitization of a cosmetic product according to results from Induction phase and Challenge Phase. In parallel, a conclusion of the induction phase related to the cutaneous compatibility, could be drawn according to the calculation of the Mean Irritation Index (M.I.I.) global which was obtained according to average of the calculation of the daily Mean Irritation Index:

# Daily M. I. I. = $\frac{\sum(\overline{x} \text{ of the erythema and oedema grade})}{\text{Number of panelists}}$

M.I.I.	Product Classification
M.I.I.=0.000	Non-Irritating (NI)/Very Good Cutaneous Compatibility
M.I.I. <0.022	Non-Irritating (NI) / Good Cutaneous Compatibility
0.022 <u>&lt; </u> M.I.I. <0.055	Slightly Irritating (SI) / Intermediate Cutaneous Compatibility
0.055 <u>&lt;</u> M.I.I. <0.111	Moderately Irritating (NI) / Bad Cutaneous Compatibility
M.I.I. <u>≥</u> 0.111	Irritating (I) / Very Bad Cutaneous Compatibility

The obtained index is used to classify the studied cosmetic product according to the following scale:

Table 2. Cutaneous compatibility cosmetic product classification index

Page 9 of 20



# 5. RESULTS

The individual reading results are presented in Annex II.

Next table showed the Global M.I.I. after induction phase.

M.I.I.	Results	No. reactive panelists	% reactive panelists
0,033	Slightly Irritating (SI)/Intermediate Cutaneous Compatibility	18	31%

Next table shows the results of Challenge or Memory phase:

Challanaa	No. reactiv	ve panelists	% reactive	panelists
Challenge (Memory	Induction area	Virgin area	Induction area	Virgin area
phase)	0	0	0%	0

The individual reading results are presented in Annex III.

# Allergenicity result:

The allergenicity result was set up from the results obtained in the induction phase and in the memory phase (induction area and virgin area).

Results	No. panelists showing some kind of allergic reaction	% reactive panelists
	0	0%

Page 10 of 20



# 6. SAMPLES AND DOCUMENTS TO BE STORED

The following documentation relating to the study will be stored in the facilities of Zurko Research following the provisions of ISO 9001:2015:

- Informed Consent Forms signed
- Study protocol and its modifications (signed)
- Primary data
- Final report and its modifications (signed)
- Documents provided by the sponsor

The documents will be stored during 5 years. After 5 years the sponsor will be asked about the possibility of extension because of the commercialization of the tested element.

A sample of the evaluated product (sufficient quantity for the execution of the study) will be stored in the Zurko Research samples library for 1 year from the start date of the study.

## 7. BIBLIOGRAPHICAL REFERENCES

1. SCCS (Scientific Committee on Consumer Safety), SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation 10th revision, 24-25 October 2018, SCCS/1602/18.

2. Patel, S.M., E. Patrick, and H.I. Maibach, 1976 "Animal, Human, and In Vitro Test Methods for Predicting Skin Irritation". Dermatotoxicology, Chpt. 33; 5<sup>th</sup> Ed., F.N. Marzulli; H.I. Maibach; Taylor and Frances.

3. Pauline M. McNamee, Anne Marie Api, David A. Basketter, G. Frank Gerberick, Deborah A. Gilpin, Barbar M. Hall, Ian Jowsey, Michael K. Robinson. A review of critical factors in the conduct and interpretation of the human repeat insult patch test. Regulatory Toxicology and Pharmacology 52 (2008) 24-34.

4. Valerie T. Politano, Anne Marie Api. The Research Institute for Fragance Materials' human repeated insult patch test protocol. Regulatory Toxicology and Pharmacology 52 (2008) 35-38.

5. Nueva Clasificación de tipos piel y sus implicaciones en Dermatología Cosmética. Revisión Dermatología Venezolana. Vol. 43, Nº 4, 2005. Leslie Baumann, Sadegh Amini, Eduardo Weiss.

Page 11 of 20




# SIGNATURES

The undersigned declare that this study has been carried out in the essence of the Clinical Good Practices (Guideline for good clinical practice E6 (R2) of June 14<sup>th</sup> 2017, EMA/CHMP/ICH/135/1995 of May 1<sup>st</sup> 1996, European Parliament and Council Guideline 2001/20/CE – May 1<sup>st</sup> 2001).

The results here presented reflect accurately and completely the raw data of the study.

**Researcher:** I, the undersigned, Jesús González Cuartero, declare that this study has been **carried out** under my responsibility.



**Dermatology Team**: Zurko's dermatology team, led by the dermatologist Javier Pedraz (medical license number: 283706434), and Natalia Zawierta, as adjunct dermatologist, declare that this study has been **reviewed** under their responsibility. In representation,





	Panelists	0.000	Cou		Black Law
Ref.	Acronym	Age	Sex	Skin type	Photo-type
1	V01	59	F	S	Ш
2	V02	51	F	S	IV
3	V03	21	F	S	Ш
4	V04	65	F	S	IV
5	V05	29	М	S	Ш
6	V06	51	F	S	II
7	V07	51	F	S	Ш
8	V09	31	F	S	II
9	V11	58	М	S	IV
10	V13	40	F	S	III
11	V14	33	F	S	Ш
12	V15	51	F	S	Ш
13	V16	30	F	S	IV
14	V17	23	М	S	Ш
15	V18	18	F	S	Ш
16	V19	45	F	S	IV
17	V21	36	М	S	Ш
18	V22	28	F	S	Ш
19	V23	21	F	S	Ш
20	V24	44	F	S	IV
21	V26	31	М	S	Ш
22	V27	66	М	S	Ш
23	V28	39	F	S	Ш
24	V30	51	F	S	II
25	V32	52	F	S	IV
26	V33	26	F	S	IV

Page 13 of 20



27   V34   48   M   S   III     28   V35   50   M   S   III     29   V36   42   F   S   IV     30   V37   68   F   S   II     31   V38   54   F   S   II     32   V39   63   F   S   III     33   V40   41   F   S   III     34   V41   62   F   S   III     35   V42   63   F   S   III     36   V43   43   F   S   III     36   V42   63   F   S   III     37   V44   35   F   S   III     38   V45   55   M   S   III     39   V46   51   F   S   III     40   V47   25   F   S   III     41   V48   36   F   S   III  <			-	luuy lejelence. v	v_ee min 1750D	1_000_21_001
29V3642FSIV30V3768FSII31V3854FSII32V3963FSIII33V4041FSII34V4162FSIII35V4263FSIII36V4343FSIII37V4435FSIII38V4555MSIII39V4651FSIII40V4725FSIII41V4836FSIII43V5022FSIII44V5356FSIII45V5431FSIII46V5536FSIII47V5626FSIII48V5740FSIII50V5950FSII51V6055FSII52V6145FSII	27	V34	48	М	S	Ш
30     V37     68     F     S     II       31     V38     54     F     S     II       32     V39     63     F     S     III       33     V40     41     F     S     III       34     V41     62     F     S     III       35     V42     63     F     S     III       36     V43     43     F     S     III       36     V43     43     F     S     III       37     V44     35     F     S     III       38     V45     55     M     S     III       39     V46     51     F     S     III       40     V47     25     F     S     III       41     V48     36     F     S     III       42     V49     54     F     S     III       43     V50     22     F <td< th=""><th>28</th><th>V35</th><th>50</th><th>М</th><th>S</th><th>Ш</th></td<>	28	V35	50	М	S	Ш
31     V38     54     F     S     II       32     V39     63     F     S     III       33     V40     41     F     S     II       34     V41     62     F     S     III       35     V42     63     F     S     III       36     V43     43     F     S     III       36     V43     43     F     S     III       37     V44     35     F     S     III       38     V45     55     M     S     III       39     V46     51     F     S     III       40     V47     25     F     S     III       41     V48     36     F     S     III       41     V48     36     F     S     III       43     V50     22     F     S     III       44     VS3     56     F <td< th=""><th>29</th><th>V36</th><th>42</th><th>F</th><th>S</th><th>IV</th></td<>	29	V36	42	F	S	IV
32V3963FSIII33V4041FSII34V4162FSIII35V4263FSIII36V4343FSIII37V4435FSIII38V4555MSIII39V4651FSIII40V4725FSIII41V4836FSIII42V4954FSIII43V5022FSIII44V5356FSIII45V5431FSIII46V5536FSIII48V5740FSIII50V5950FSII51V6055FSII52V6145FSII	30	V37	68	F	S	II
33V4041FSII34V4162FSIII35V4263FSIII36V4343FSIII37V4435FSIII38V4555MSIII39V4651FSIII40V4725FSIII41V4836FSIII42V4954FSIII43V5022FSIII44V5356FSIII45V5431FSIII46V5536FSIII48V5740FSIII50V5950FSIII51V6055FSIII52V6145FSIII	31	V38	54	F	S	Ш
34V4162FSIII35V4263FSIII36V4343FSIII37V4435FSIII38V4555MSIII39V4651FSIII40V4725FSIII41V4836FSIII42V4954FSIII43V5022FSIII44V5356FSIII45V5431FSIII46V5536FSIII48V5740FSIII49V5822FSIII50V5950FSIII51V6055FSIII52V6145FSIII	32	V39	63	F	S	Ш
35     V42     63     F     S     III       36     V43     43     F     S     III       37     V44     35     F     S     III       38     V45     55     M     S     III       39     V46     51     F     S     III       40     V47     25     F     S     III       41     V48     36     F     S     III       42     V49     54     F     S     III       43     V50     22     F     S     III       44     V53     56     F     S     III       44     V53     56     F     S     III       45     V54     31     F     S     III       46     V55     36     F     S     III       47     V56     26     F     S     III       48     V57     40     F     <	33	V40	41	F	S	Ш
36V4343FSIII37V4435FSIII38V4555MSIII39V4651FSIII40V4725FSIII41V4836FSIII42V4954FSIII43V5022FSIII44V5356FSIII45V5431FSIII46V5536FSIII47V5626FSIII48V5740FSIII50V5950FSIII51V6055FSIII52V6145FSIII	34	V41	62	F	S	III
37     V44     35     F     S     III       38     V45     55     M     S     III       39     V46     51     F     S     III       40     V47     25     F     S     III       41     V48     36     F     S     III       41     V48     36     F     S     III       42     V49     54     F     S     III       43     V50     22     F     S     III       44     V53     56     F     S     III       44     V53     56     F     S     III       45     V54     31     F     S     III       46     V55     36     F     S     III       48     V57     40     F     S     III       48     V57     40     F     S     III       50     V58     22     F     <	35	V42	63	F	S	Ш
38V4555MSIII39V4651FSIII40V4725FSIII41V4836FSIII42V4954FSIII43V5022FSIII44V5356FSIII45V5431FSIII46V5536FSIII47V5626FSIII48V5740FSIII49V5822FSIII50V5950FSIII51V6055FSIII52V6145FSIII	36	V43	43	F	S	III
39     V46     51     F     S     III       40     V47     25     F     S     III       41     V48     36     F     S     III       42     V49     54     F     S     III       43     V50     22     F     S     III       44     V53     56     F     S     III       44     V53     56     F     S     III       45     V54     31     F     S     III       46     V55     36     F     S     III       47     V56     26     F     S     III       48     V57     40     F     S     III       49     V58     22     F     S     III       50     V59     50     F     S     III       51     V60     55     F     S     III	37	V44	35	F	S	Ш
40V4725FSIII41V4836FSIII42V4954FSIII43V5022FSIII44V5356FSIII45V5431FSIII46V5536FSIII47V5626FSIII48V5740FSIII49V5822FSIII50V5950FSII51V6055FSIII	38	V45	55	М	S	III
41   V48   36   F   S   III     42   V49   54   F   S   III     43   V50   22   F   S   III     44   V53   56   F   S   III     45   V54   31   F   S   III     46   V55   36   F   S   III     47   V56   26   F   S   III     48   V57   40   F   S   III     49   V58   22   F   S   III     50   V57   40   F   S   III     51   V60   55   F   S   III     52   V61   45   F   S   III	39	V46	51	F	S	Ш
42     V49     54     F     S     III       43     V50     22     F     S     III       44     V53     56     F     S     III       45     V54     31     F     S     III       46     V55     36     F     S     III       47     V56     26     F     S     III       48     V57     40     F     S     III       49     V58     22     F     S     III       50     V57     40     F     S     III       51     V60     55     F     S     III       52     V61     45     F     S     III	40	V47	25	F	S	III
43V5022FSIII44V5356FSIII45V5431FSIII46V5536FSIII47V5626FSIII48V5740FSIII49V5822FSIII50V5950FSIII51V6055FSIII52V6145FSIII	41	V48	36	F	S	Ш
44   V53   56   F   S   III     45   V54   31   F   S   III     46   V55   36   F   S   III     47   V56   26   F   S   IV     48   V57   40   F   S   IV     49   V58   22   F   S   III     50   V59   50   F   S   III     51   V60   55   F   S   III     52   V61   45   F   S   III	42	V49	54	F	S	III
45     V54     31     F     S     III       46     V55     36     F     S     IV       47     V56     26     F     S     III       48     V57     40     F     S     IV       49     V58     22     F     S     III       50     V59     50     F     S     II       51     V60     55     F     S     III       52     V61     45     F     S     III	43	V50	22	F	S	Ш
46     V55     36     F     S     IV       47     V56     26     F     S     III       48     V57     40     F     S     IV       49     V58     22     F     S     III       50     V59     50     F     S     III       51     V60     55     F     S     III       52     V61     45     F     S     III	44	V53	56	F	S	III
47     V56     26     F     S     III       48     V57     40     F     S     IV       49     V58     22     F     S     III       50     V59     50     F     S     III       51     V60     55     F     S     III       52     V61     45     F     S     III	45	V54	31	F	S	Ш
48     V57     40     F     S     IV       49     V58     22     F     S     III       50     V59     50     F     S     III       51     V60     55     F     S     III       52     V61     45     F     S     III	46	V55	36	F	S	IV
49     V58     22     F     S     III       50     V59     50     F     S     II       51     V60     55     F     S     III       52     V61     45     F     S     III	47	V56	26	F	S	Ш
50     V59     50     F     S     II       51     V60     55     F     S     III       52     V61     45     F     S     III	48	V57	40	F	S	IV
51     V60     55     F     S     III       52     V61     45     F     S     III	49	V58	22	F	S	Ш
52 V61 45 F S III	50	V59	50	F	S	Ш
	51	V60	55	F	S	Ш
	52	V61	45	F	S	Ш

M: male, F: female; R: non-sensitive, S: sensitive

Two panelists (V08, V51) left the study due to reasons unrelated to it. Seven exclusions (V10, V12, V20, V25, V29, V31, V52) were decided for the researcher due to exaggerated reaction to the product.

Page 14 of 20



# Annex II: Individual results from Induction phase

Pan	elists								Reaction in Induction Phase (according to Table 1)																			
			DAY 3			DAY 5			DAY 8			DAY 10			DAY 12			DAY 15			DAY 17			DAY 19			DAY 22	
Ref	Acr.	E	OE	Ot	E	OE	Ot	E	OE	Ot	Е	OE	Ot	E	OE	Ot	Е	OE	Ot	Е	OE	Ot	E	OE	Ot	Е	OE	Ot
1	V01	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2	V02	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3	V03	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4	V04	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
5	V05	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
6	V06	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	V07	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	V09	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9	V10	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	/	/	/	/	/	/	/	/	/
10	V11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
11	V12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	/	/	/	/	/	/	/	/	/
12	V13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	V14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
14	V15	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
15	V16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	V17	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Page 15 of 20



Pan	elists										Read	tion i	n Indu	ction	Phase	(acco	rding	to Tal	ole 1)	-								
		DAY 3				DAY 5			DAY 8		[	DAY 10	)		DAY 12			DAY 1	5		DAY 17	7	DAY 19				DAY 22	2
Ref	Acr.	E	OE	Ot	Ε	OE	Ot	Е	OE	Ot	Е	OE	Ot	Е	OE	Ot	Е	OE	Ot	E	OE	Ot	Ε	OE	Ot	Е	OE	Ot
17	V18	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
18	V19	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
19	V20	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0
20	V21	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
21	V22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22	V23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
23	V24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	V25	1	0	0	0	0	0	2	0	0	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/
25	V26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
26	V27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
27	V28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
28	V29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	1	0	/	/	/	/	/	/
29	V30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
30	V31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	/	/	/	/	/	/	/	/	/
31	V32	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
32	V33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
33	V34	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Page 16 of 20



Pan	elists										Read	tion i	n Indu	ction	Phase	(acco	rding	to Tak	ole 1)			_				_		
		DAY 3				DAY 5			DAY 8		[	DAY 10	)		DAY 12			DAY 1	5		DAY 17	7		DAY 19	)		DAY 22	2
Ref	Acr.	E	OE	Ot	Ε	OE	Ot	E	OE	Ot	Е	OE	Ot	Е	OE	Ot	Е	OE	Ot	Е	OE	Ot	E	OE	Ot	Е	OE	Ot
34	V35	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
35	V36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
36	V37	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
37	V38	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
38	V39	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
39	V40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
40	V41	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0
41	V42	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
42	V43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
43	V44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
44	V45	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
45	V46	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
46	V47	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
47	V48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
48	V49	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
49	V50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0
50	V52	0	0	0	0	0	0	0	0	0	3	0	0	/	/	/	/	/	/	/	/	/	/	/	/	/	/	/

# Page 17 of 20



Pan	elists	lists Reaction in Induction Phase (according to Table 1)												_														
		DAY 3			DAY 5		DAY 8			DAY 10		DAY 12		DAY 15		DAY 17		7	DAY 19		)		DAY 22	2				
Ref	Acr.	E	OE	Ot	E	OE	Ot	E	OE	Ot	E	OE	Ot	E	OE	Ot	Е	OE	Ot	E	OE	Ot	E	OE	Ot	E	OE	Ot
51	V53	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
52	V54	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
53	V55	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
54	V56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
55	V57	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
56	V58	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
57	V59	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
58	V60	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
59	V61	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	aily .I.I.	0,008 0,000			0,0	017		0,026			0,	018		0,088			0,065			0,047			0,047					
	Global M.I.I. 0,033																											

0: non-visible erythema, 1: slight erythema, 2: moderate erythema, 3: intense erythema

P: papules, PU: pustules, V: vesicles, B: bullae, S: spreading, W: weeping, X: residual pigmentation



Da	nelists		Reaction in Challenge Memory phase												
Fa	nensts		nductio	on Area	ì		Virgin	Area		Allergeniciy					
Ref.	Acronym	D36	D38	D39	D40	D36	D38	D39	D40	Result (-/+)					
1	V01	0	0	0	0	0	0	0	0	-					
2	V02	0	0	0	0	0	0	0	0	-					
3	V03	0	0	0	0	0	0	0	0	-					
4	V04	0	0	0	0	0	0	0	0	-					
5	V05	0	0	0	0	0	0	0	0	-					
6	V06	0	0	0	0	0	0	0	0	-					
7	V07	0	0	0	0	0	0	0	0	-					
8	V09	0	0	0	0	0	0	0	0	-					
9	V11	0	0	0	0	0	0	0	0	-					
10	V13	0	0	0	0	0	0	0	0	-					
11	V14	0	0	0	0	0	0	0	0	-					
12	V15	0	0	0	0	0	0	0	0	-					
13	V16	0	0	0	0	0	0	0	0	-					
14	V17	0	0	0	0	0	0	0	0	-					
15	V18	0	0	0	0	0	0	0	0	-					
16	V19	0	0	0	0	0	0	0	0	-					
17	V21	0	0	0	0	0	0	0	0	-					
18	V22	0	0	0	0	0	0	0	0	-					
19	V23	0	0	0	0	0	0	0	0	-					
20	V24	0	0	0	0	0	0	0	0	-					
21	V26	0	0	0	0	0	0	0	0	-					
22	V27	0	0	0	0	0	0	0	0	-					
23	V28	0	0	0	0	0	0	0	0	-					
24	V30	0	0	0	0	0	0	0	0	-					
25	V32	0	0	0	0	0	0	0	0	-					
26	V33	0	0	0	0	0	0	0	0	-					
27	V34	0	0	0	0	0	0	0	0	-					
28	V35	0	0	0	0	0	0	0	0	-					
29	V36	0	0	0	0	0	0	0	0	-					

# Annex III: Individual Results from Challenge phase

Page 19 of 20



Da	nelists		Reaction in Challenge Memory phase												
Fa	ileiists		nducti	on Area			Virgin	Area		Allergeniciy					
Ref.	Acronym	D36	D38	D39	D40	D36	D38	D39	D40	Result (-/+)					
30	V37	0	0	0	0	0	0	0	0	-					
31	V38	0	0	0	0	0	0	0	0	-					
32	V39	0	0	0	0	0	0	0	0	-					
33	V40	0	0	0	0	0	0	0	0	-					
34	V41	0	0	0	0	0	0	0	0	-					
35	V42	0	0	0	0	0	0	0	0	-					
36	V43	0	0	0	0	0	0	0	0	-					
37	V44	0	0	0	0	0	0	0	0	-					
38	V45	0	0	0	0	0	0	0	0	-					
39	V46	0	0	0	0	0	0	0	0	-					
40	V47	0	0	0	0	0	0	0	0	-					
41	V48	0	0	0	0	0	0	0	0	-					
42	V49	0	0	0	0	0	0	0	0	-					
43	V50	0	0	0	0	0	0	0	0	-					
44	V53	0	0	0	0	0	0	0	0	-					
45	V54	0	0	0	0	0	0	0	0	-					
46	V55	0	0	0	0	0	0	0	0	-					
47	V56	0	0	0	0	0	0	0	0	-					
48	V57	0	0	0	0	0	0	0	0	-					
49	V58	0	0	0	0	0	0	0	0	-					
50	V59	0	0	0	0	0	0	0	0	-					
51	V60	0	0	0	0	0	0	0	0	-					
52	V61	0	0	0	0	0	0	0	0	-					

0: non-visible erythema, 1: slight erythema, 2: moderate erythema, 3: intense erythema

Confidential document – Property of Zurko Research

Page 20 of 20